
    
      The primary efficacy is evaluated by demonstration that the product provides a lower bound of
      the 95% confidence interval of percent responders that is greater than or equal to 70% On the
      abdominal site, a responder is defined as a subject with a 2-log10/cm2 bacterial reduction at
      10 minutes and for whom the skin flora does not return to baseline at 6 hours.

      On the inguinal site, a responder is defined as a subject with a 3-log10/cm2 bacterial
      reduction at 10 minutes and for whom the skin flora does not return to baseline at 6 hours.
    
  